Anthony Letai, Director of National Cancer Institute, shared on X:
“Good news on Metastatic Breast Cancer Awareness Day
A new Phase 3 pill combo kept tumors stable for nearly double the time for certain types of advanced breast cancer (10 months vs 5.5 months in ER+/HER2-). Nice work Dana-Farber and team!”
Title: Giredestrant plus Everolimus in Advanced Breast Cancer
Authors: Erica L. Mayer, Sara M. Tolaney, Miguel Martín, Gregory A. Vidal, Luca Moscetti, Komal L. Jhaveri, Adam Brufsky, William J. Gradishar, Andreas Schneeweiss, Naoki Niikura, Anne Favret, Margarita Alfie, Keun Seok Lee, Sarah Khan, Merilin B. Feldman, Bann-mo Day, Lisa H. Lam, Walter C. Darbonne, Mona D. Shah, Kristin L. Griffiths, Gillian DiLallo, Pablo D. Pérez-Moreno, Hope S. Rugo
You may also find this interesting:
Risk-Adapted Approach to Neoadjuvant Therapy in HER2-Positive Early Breast Cancer
